Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1/A Registration statement (foreign)
- 3.2 EX-3.2
- 4.1 EX-4.1
- 8.2 EX-8.2
- 10.1 EX-10.1
- 10.14 EX-10.14
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 15.1 EX-15.1
- 23.1 EX-23.1
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- 99.10 EX-99.10
- EX-FILING FEES Ex-filing Fees
Associated filings
- 17 Apr 23 424B4 Prospectus supplement with pricing info
- 3 Apr 23 EFFECT Notice of effectiveness
- 31 Mar 23 FWP Free writing prospectus
- 30 Mar 23 F-1/A Registration statement (foreign) (amended)
- 27 Mar 23 F-1/A Registration statement (foreign) (amended)
- 15 Mar 23 F-1/A Registration statement (foreign) (amended)
- 27 Feb 23 FWP Free writing prospectus
- 21 Feb 23 F-1/A Registration statement (foreign) (amended)
-
31 Jan 23 F-1/A Registration statement (foreign) (amended)
- 18 Nov 22 F-1 Registration statement (foreign)
GDTC similar filings
Filing view
External links
Exhibit 99.1
Consent to be Named as a Director Nominee
In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed Therapeutics Limited in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
| Dated: January 31, 2023 | |
/s/ Dr. ZENG Jieming | |
| Dr. ZENG Jieming |